Literature DB >> 25896679

Current status of nuclear cardiology in Japan: Ongoing efforts to improve clinical standards and to establish evidence.

Keiichiro Yoshinaga1, Nagara Tamaki.   

Abstract

Nuclear cardiology imaging tests are widely performed in Japan as clinical practice. The Japanese nuclear cardiology community has developed new diagnostic imaging tests using (123)I-beta-methyl-p-iodophenyl-pentadecanoic acid, (123)I-metaiodobenzylguanidine, and (18)F-fluorodeoxyglucose PET for detecting cardiac involvement in sarcoidosis. These tests have become popular worldwide. The Japanese Circulation Society and the Japanese Society of Nuclear Cardiology have published clinical imaging guidelines showing indications and standards for the new imaging tests. JSNC is currently striving to improve the standard of clinical practice and is promoting research activities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896679     DOI: 10.1007/s12350-015-0136-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  51 in total

Review 1.  The role of radionuclide imaging in heart failure.

Authors:  Vinay Gulati; Gilbert Ching; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

2.  Less invasive approach to the assessment of coronary artery disease. -Morphological vs. physiological paradigm-.

Authors:  Naoya Matsumoto; Yasuyuki Suzuki; Ken Nagao; Atsushi Hirayama; Yuichi Sato
Journal:  Circ J       Date:  2011-05-28       Impact factor: 2.993

3.  Guidelines in review: 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.

Authors:  Arka Chatterjee; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2014-09-11       Impact factor: 5.952

4.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

Review 5.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

6.  Treating the right patient at the right time: access to cardiovascular nuclear imaging.

Authors:  K Y Gulenchyn; A J McEwan; M Freeman; M Kiess; B J O'Neill; R S Beanlands
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

Review 7.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

Review 8.  Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases.

Authors:  Masao Miyagawa; Rami Yokoyama; Yoshiko Nishiyama; Akiyoshi Ogimoto; Jitsuo Higaki; Teruhito Mochizuki
Journal:  Circ J       Date:  2014-05-09       Impact factor: 2.993

9.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more
  6 in total

Review 1.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

2.  Comparisons and contrasts in the practice of nuclear cardiology in the United States and Japan.

Authors:  E Gordon DePuey
Journal:  J Nucl Cardiol       Date:  2016-12       Impact factor: 5.952

3.  Improving the worldwide quality of nuclear cardiology practice and research: The role of the official journal.

Authors:  Keiichiro Yoshinaga; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2016-09-07       Impact factor: 5.952

4.  How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US.

Authors:  Mark I Travin; Ichiro Matsunari; Gregory S Thomas; Kenichi Nakajima; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2018-09-03       Impact factor: 5.952

5.  123I-BMIPP, a Radiopharmaceutical for Myocardial Fatty Acid Metabolism Scintigraphy, Could Be Utilized in Bacterial Infection Imaging.

Authors:  Yuka Muranaka; Asuka Mizutani; Masato Kobayashi; Koya Nakamoto; Miki Matsue; Fumika Takagi; Kenichi Okazaki; Kodai Nishi; Kana Yamazaki; Ryuichi Nishii; Naoto Shikano; Shigefumi Okamoto; Hideki Maki; Keiichi Kawai
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

6.  Radiopharmaceutical tracers for cardiac imaging.

Authors:  Osamu Manabe; Tatsuya Kikuchi; Arthur J H A Scholte; Mohammed El Mahdiui; Ryuichi Nishii; Ming-Rong Zhang; Eriko Suzuki; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2017-12-01       Impact factor: 5.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.